NEW YORK, NY / ACCESSWIRE / August 5, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/verrica-pharmaceuticals-inc-loss-submission-form?prid=30623&wire=1
Lead Plaintiff Deadline: August 5, 2022
Class Period: May 28, 2021 - May 24, 2022
Allegations against VRCA include that: (1) there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced a bulk solution for the Company's lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
17 Education & Technology Group Inc. (NASDAQ:YQ)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/17edtech-loss-submission-yq?prid=30623&wire=1
Lead Plaintiff Deadline: September 19, 2022
This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded 17EdTech securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with 17EdTech's December 2020 initial public offering.
Allegations against YQ include that: (1) 17EdTech's K-12 Academic AST Services would end less than a year after the Company's initial public offering; (2) as part of its ongoing regulatory efforts, Chinese authorities would imminently curtail and/or end 17EdTech's core business; and (3) as a result, defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Enochian BioSciences, Inc. (NASDAQ:ENOB)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/enochian-biosciences-inc-loss-submission-form?prid=30623&wire=1
Lead Plaintiff Deadline: September 26, 2022
Class Period: January 17, 2018 - June 27, 2022
Allegations against ENOB include that: (1) the Company's co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu's purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: